



BIOANALYTICAL SCIENCES

Quantitative PK expertise

- Expert PK assay development, validation and sample analysis for preclinical and clinical studies
- ELISA and MSD® platforms and more
- Rigorous pre-validation testing to ensure validation and sample analysis success
- Customized, science-first approach
 - Tailored to the needs of the client and specific drug development program
 - In-depth project intake with comprehensive scientific support
 - Sound strategies coupled with expert solutions

Assay Formats

- Ligand binding assays
- Drug target capture
- Anti-drug idiotype capture
- Custom and commercial detection
- Hybridization ELISAs for ASOs
- Immuno-PCR
- Cell-based PK assays

Therapeutic Modalities

- Antibodies
- Fabs
- scFvs
- Bi/multi-specific antibodies
- Pegylated proteins
- IgMs
- Biosimilars (Humira®, Herceptin®, Enbrel®, Eylea®)
- Antibody drug conjugates
- Antibody oligo conjugates
- Fusion proteins
- Adnectin fusions
- Peptides
- Therapeutic enzymes
- ASOs
- AAVs
- Oncolytic viruses
- Transgene products
- Allogenic cell therapies
- Exosomes
- Virus-like particles

NEW IN 2024

Project sponsors have direct access for consultation at ILX scientific office hours

- Assay development challenges
- Bioanalytical & biomarker strategies
- Alignment with regulator guidance
- Gather insights from regulatory interactions
- Comprehensive and clinically relevant drug development expertise

Matrices

- Aqueous humor
- Bronchial/alveolar lavage fluid
- Cornea, lens, RPE/choroid, retina
- CSF
- Duodenum, ileum, jejunum
- Feces
- Large intestine
- Lung
- Muscle
- Plasma
- Saliva
- Serum
- Skeletal muscle/ocular skeletal muscle
- Skin
- Synovial fluid
- Urine
- Vitreous humor
- Whole blood